24/12/19 – New Drug Approved by FDA
The U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi®) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC).  Enzalutamide has previously been FDA-approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).
Read more…

1/2/18 – Processed food not prostate cancer risk
Over the past few decades, diets in many countries have shifted towards an increase in the consumption of ultra-processed foods: foods generally characterised by their low nutritional quality, higher content of total and saturated fats, added salt and sugar and lower fibre and vitamin density.
Read more

1/1/18 – Socioeconomic status and its effect on cancer outcomes
A study in Sweden has shown that patients with high socioeconomic status (SES) have better cancer outcomes than patients with a low SES when using the national health care system.
Read more

12/12/17 – Advanced Prostate Cancer
In most cases, prostate cancer is cured by surgical removal of the tumour and/or by radiotherapy. However, 20% of patients will need treatment to remove tumour cells but this treatment ceases to be effective after two or three years and the cancer develops further. Once this stage of the disease has been reached, there is no cure. A team headed by Xavier Salvatella, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona), has discovered a new avenue through which to attack prostrate cancer cells that have developed drug-resistance. 
Read more

26/9/17 – Hope For Cure
A breakthrough in treatment for prostate cancer could cure thousands of men whose disease was thought to be incurable, research suggests. The Institute of Cancer Research said the findings were a “great leap forward” which could help around 3,000 men a year for whom there would otherwise be little hope. The pioneering study, with The Royal Marsden, found that the highly targeted form of radiotherapy, which shapes radiation beams to tumours, could stop the disease in its tracks.
Read more

7/7/16 – Inherited Genetic Mutations Found
Results from a PCF-funded study reported that ~12% of men with metastatic prostate cancer carry inherited cancer-promoting mutations in DNA repair genes. These findings have important implications for treatment selection and for patients’ families. All men with metastatic prostate cancer are now encouraged to speak with their physician about genetic testing and counseling for male and female family members to assess risk for certain cancers.
Read more

6/7/16 – Genetic test for prostate cancer
Men with advanced prostate cancer could be checked for high-risk family genes because they are fairly common, affect treatment and can be passed on to their children, say experts. According to the international researchers, more than one in every 10 men with the advanced disease carries a faulty gene, inherited from a parent. One of the genes is BRCA1 – already linked to breast and ovarian cancer. The study, in the journal NEJM, is the largest of its kind to date. It included nearly 700 patients with aggressive prostate cancer and found that a “significant proportion” of these men are born with mutant DNA. Men with these genes may benefit from newer drug treatments that exploit the damaged genetic code to locate and kill off cancer cells.
Read more

5/7/16 – Exciting New Development
Scientists at Swansea University say they have made a breakthrough which could revolutionise prostate cancer treatment. Researchers at the university’s School of Medicine have developed a way of shrinking cancer cells using a harmless strain of salmonella bacteria. It targets the tumour but leaves healthy tissue unaffected. The university’s Dr Claire Morgan described it as a “game-changer”.
Read more

2/6/16 – Reduce your waistline
Men with larger waistlines could be at higher risk of developing aggressive prostate cancer, a study has suggested. Research on 140,000 men from eight European countries found that a 4in (10cm) larger waist circumference could increase the chances of getting the cancer by 13%. Men were most at risk when their waist was bigger than 37in (94cm), the University of Oxford study found.
Read more

2/5/16 – New drugs promising
A new type of drug could benefit men with aggressive prostate cancer that is no longer responding to treatment, researchers from the Institute of Cancer Research have said. In a study on mice, Hsp90 inhibitors were found to strip cancer cells of defences against hormone treatments. This makes the drugs particularly promising for treating drug-resistant cancers, the research team said. Prostate cancer is the most common cancer in men in the UK.
Read more

21/3/16 – U-Turn in England over new drugs
Patients with prostate cancer in England will now have early access to a drug that can delay the need for chemotherapy. The National Institute for Health and Care Excellence (NICE) now agrees that abiraterone is affordable.
Read more

6/1/16 – Exercise helps cut risk
UK researchers are carrying out a trial to see if exercise therapy can help men with prostate cancer. The Sheffield Hallam University team, backed by Cancer Research UK, have a hunch that physical activity can help the body stop tumours from spreading. They are asking 50 men with prostate cancer that has not yet spread to put the theory to the test for 12 months. They hope to show that aerobic exercise is a treatment in its own right and should be offered on the NHS.
Read more

8/9/15 – New drug approved in Wales
A new treatment for men with advanced prostate cancer is set to be made available on the Welsh NHS, it has been announced. The All Wales Medicines Strategy Group (AWMSG) has approved the use of Enzalutamide, also known as Xtandi, to help prolong the lives of prostate cancer patients who have become resistant to their first hormone treatment. Prostate cancer is the most common cancer in Welsh men, with more than 2,500 men being diagnosed every year.
Read more